Introduction
Chronic obstructive pulmonary disease (COPD) is a highly prevalent 1 and debilitating disease that has a significant impact on patient quality of life and the costs borne by the health care system. 2, 3 An exacerbation of COPD is the most common condition that requires hospital admission, 4 and contributes substantially to the related economic impact. [5] [6] [7] Therefore, COPD exacerbations have been considered the most important target for reducing costs. A study in the UK National Health Service (NHS) in 2001 showed that the total excess primary care cost associated with acute exacerbations of chronic bronchitis in the COPD-diagnosed population was £35.7 million. This included the excess cost of all prescription medications, general practitioner (GP) consultations, hospital emergency room visits, and inpatient hospital episodes. 8 Similarly, a retrospective analysis of data from a large national health plan database in the US showed that COPD-related mean annual costs were 56% higher for patients with two or more exacerbations compared with the overall population of COPD patients. 8 This finding has also been reflected in other studies conducted across Europe and the US, suggesting that prevention of exacerbations requiring hospitalization is the foremost factor critical in the development of a cost-effective disease management strategy. [5] [6] [7] 10, 11 In contrast, symptomatic patients who are at a low risk of exacerbation represent an unexplored population with respect to health care costs. These patients continue to report symptoms, potentially consuming significant primary care resources. Therefore, it is important to assess the severity of these symptoms and their impact on health care resource utilization. The annual administration of the Medical Research Council (MRC) dyspnea scale in the UK primary care setting instituted by the UK NHS Quality Outcomes Framework (since April 2009) allows such quantitative assessment of symptoms of dyspnea. 12 A previous study using this dyspnea recording has found a high prevalence of dyspnea in the primary care COPD population in the UK. 13 This study evaluated the primary care COPD population and its costs using the Clinical Practice Research Datalink (CPRD) database. The study objectives were to estimate resource use and the associated costs among patients classified by no, one, and two or more exacerbations and to compare resource use and costs between different levels of exacerbations across the Global initiative for chronic Obstructive Lung Disease (GOLD) stages of airflow obstruction and MRC dyspnea categories.
Materials and methods study design
This was a retrospective cohort study of COPD patients identified from primary care in the UK using the CPRD. CPRD is the NHS observational data and interventional research service, jointly funded by the NHS National Institute for Health Research and the Medicines and Healthcare products Regulatory Agency.
14 In this study, we used the primary care electronic medical records database part of the CPRD, formerly known as the General Practice Research Database. 14 About 660 general practices participate in the CPRD; the database contains data for about 11 million patients, mostly from England and Wales. The COPD cohort study design and analysis methods (protocol WEUSKOP5903), prior to the cost estimation and modeling described herein, were approved by the CPRD Independent Scientific Advisory Committee.
Patients aged 40 years or older with one or more records for diagnosis of COPD (Table S1) on or after April 1, 2009 were included. Date of the first recorded COPD diagnosis on or after April 1, 2009 was taken as the cohort entry date. Patients were required to have at least a 12 month history before and after cohort entry and a record of forced expiratory volume in one second/forced vital capacity (FEV 1 /FVC) ,0.7. The observation period consisted of a fixed period of 12 months of follow-up after cohort entry. The corresponding 12 month data prior to cohort entry have been referred to as the pre-observation period. Health care resource use during the observation and pre-observation periods was captured as moderate-to-severe exacerbations, GP interactions, and non-COPD hospitalizations. Exacerbations were further split into moderate and severe events. A moderate exacerbation was defined as an episode characterized by management with antibiotics commonly used in COPD exacerbations and oral corticosteroids (within 5 days of initiation of antibiotics), and/or a medical diagnosis of COPD exacerbation. A severe exacerbation was defined as an episode characterized by hospitalization for COPD. These were selected using an algorithm that identified hospital admissions of specific COPD cause or general admissions with a record of COPD diagnosis or medication up to 3 days before and 7 days after the index hospitalization date. The first event qualifying as an exacerbation was considered as the start date of the episode. Thereafter, a 14 day moving window 15 was applied to identify at least 2 weeks of an exacerbation event-free period to ensure that a relapse was not considered a separate exacerbation. GP interactions were recorded and classified as administrative contact, surgery correspondence, visit to a surgery nurse, in-person surgery visit, out-of-office GP visit, or a GP home visit. Non-COPD hospitalizations were defined as hospital admission for specific non-COPD cause or general hospital admissions (without a specific cause) with no record of COPD diagnosis or medication recorded around this event.
Patients were classified by their moderate-to-severe exacerbation frequency (no, one, or two or more) during the observation period. Further, exacerbation frequency and medications in the pre-observation period and comorbidities at baseline were recorded. All costs were calculated using 2011 prices (except the medication costs, which were taken from 2012) expressed as mean annual costs per patient, and summarized ( compared using the chi-square test and one-way analysis of variance. Bivariate relationships with exacerbation frequency categories were evaluated using the Cochran-Mantel-Haenszel test (for categorical or ordinal variables), polyserial correlations (for continuous variables), or negative binomial modeling with exacerbation frequency during the observation period as the predictor variable while controlling for age and gender to assess a relationship with the count data.
The cost of a severe exacerbation was estimated using the relevant COPD-related Healthcare Resource Groups (HRG) codes (DZ21A-K for short stay and long stay) further weighted by the reported annual number of episodes from the NHS reference costs. 16 In addition, it was assumed that 67% of patients would arrive at the hospital by ambulance, based on a clinical audit of COPD exacerbations in 2008. 17 Therefore, 67% of the HRG cost for ambulance transportation (code PS06B) was added to the weighted COPD HRG costs. Costs of a moderate exacerbation were compiled based on the resource use stated in the report by the GOLD Strategy Group 18 and combined with cost data from the NHS reference costs, 16 the Personal Social Services Research Unit (PSSRU) 2011, 19 and the British National Formulary 65. 20 This included a GP consultation lasting 11.7 minutes, an accident and emergency visit with no admission (in 29% of cases), and a prescription of prednisolone (30 mg) and co-amoxiclav (500 mg). 21 The cost of a non-COPD hospitalization was estimated as a weighted average of short-stay and long-stay hospital episodes from PSSRU costs. 19 The costs of a GP visit in surgery and a GP visit at home were estimated to be £36 and £121, respectively, based on PSSRU costs. 19 The cost of an out-of-office GP visit was assumed to be equivalent to a GP home visit, and the cost of a GP administrative contact (£22) was assumed to be equivalent to a phone consultation at a GP surgery. The cost of a nurse visit at a GP practice was estimated to be £13 based on a typical 15.5-minute face to face consultation, and the cost of a GP correspondence was estimated to be £3 based on 30% indirect costs of a typical non-face to face consultation. 19 These unit costs were then applied to the corresponding annual resource use counts to calculate the total annual COPD management costs for the entire cohort and for patients with no, one, and two or more exacerbations. Costs estimated during the observation period were further summarized by the GOLD stage of airflow obstruction 22 and the level of dyspnea estimated using the MRC dyspnea scale 23 captured nearest to the cohort entry.
Results

Patient disposition and demographic characteristics
The final analytic COPD cohort consisted of 58,589 patients ( Figure S1 ) with a mean follow-up of 13.5 years in CPRD. The cohort had a mean age of 69.5 years; 46.6% of the patients were female and 33.1% were current smokers ( Table 2 ). The mean (± standard deviation) FEV 1 percent predicted value at baseline was 60.0±20.5, with a majority of patients in the GOLD 2 category. The mean MRC grade at baseline was 2.5±1.0.
The cohort consisted of 31,049 (52.9%), 14,189 (24.2%), and 13,351 (22.7%) patients experiencing no, one, and two or more episodes of exacerbation during the observation period, respectively (Table 2 ). Patients with a higher exacerbation frequency had lower percent predicted FEV 1 (P,0.0001), more dyspnea (P,0.0001), and a higher comorbidity index (P,0.0001) at or near baseline. The resources collected in the pre-observation and observation periods for each of the three groups are presented in Table 3 .
Cost of COPD treatment
The mean total annual COPD management cost per patient was £2,108 in the observation period. Of these costs, £257 was accounted for by exacerbations, £637 was from non-COPD hospitalizations, and £1,213 was due to GP interactions. The corresponding total COPD management Observed frequency/total number of patients; # negative binomial regression adjusted for age and sex was used to test any difference in event counts between patients with one and two or more exacerbations events compared with those with no exacerbation event during the 12 month follow-up (referent group). The first P-value refers to a comparison of those with one event vs no event; the second P-value refers to a comparison of those with two or more events vs those with no events. Abbreviations: COPD, chronic obstructive pulmonary disease; gP, general practitioner; na, not applicable for categories where no events in the referent group were recorded. cost in the pre-observation period was £1,826, comprising £200 due to exacerbations, £572 due to non-COPD hospitalizations, and £1,054 due to GP interactions.
When split by the frequency of moderate-to-severe exacerbations during the observation period, the total annual per patient COPD costs were £1,523, £2,405, and £3,396 for patients with no, one, and two or more exacerbations, respectively. GP interactions contributed most to these annual costs, accounting for £1,062 (69.7%) in patients with no exacerbations, £1,313 (54.6%) in patients with one exacerbation, and £1,592 (46.9%) in patients with two or more exacerbations ( Figure 1 ). For this cohort, the pre-observation mean total annual per patient COPD costs were £1,523, £1,928, and £2,420, respectively.
The estimated annual COPD management costs (excluding non-exacerbation-related medication costs) during the observation period by GOLD stages of airflow obstruction are presented in Table 4 and by level of dyspnea in Table 5 . The mean total annual COPD management costs were £1,767 for patients with mild dyspnea (MRC grade 1 or 2) and £2,534 for patients with moderate-severe dyspnea.
Similar cost escalations with an increase in dyspnea were also observed in all cost components, including exacerbations (£182 versus £342), non-COPD hospitalizations (£504 versus £787), and GP interactions (£1,081 versus £1,404). This upward trend in total annual costs and cost components was observed regardless of exacerbation frequency. This increase in total annual cost between patients with mild and moderate-severe dyspnea was £396 for patients with no exacerbations, £518 for patients with one exacerbation, and £862 for patients with two or more exacerbations in the observation period. The mean total annual COPD management costs were £2,063 for mild-moderate patients (GOLD stages 1 and 2) and £2,351 for severe patients (GOLD stages 3 and 4). When split by exacerbation frequency, total costs decreased with increase in severity among patients with no exacerbations (£1,535 versus £1,502) and patients with one exacerbation (£2,409 versus £2,382). In patients with two or more exacerbations, total costs increased with COPD severity (£3,287 versus £3,499). Among the cost components, GP interactions showed an upward trend with increase in COPD severity, regardless of the exacerbation frequency.
A majority of exacerbation costs were associated with severe exacerbations. For the entire cohort, the mean annual per patient cost of moderate and severe exacerbations was £63 and £194 in the observation period and £55 and £145 in the pre-observation period, respectively. Corresponding costs in the observation period were £67 and £295 for patients with one exacerbation and £214 and £567 for patients with two or more exacerbations.
Discussion
This study explored health care resource use and associated costs of COPD patients in the CPRD database. We focused on differences in costs by exacerbation frequency, further split by the GOLD stages of airflow obstruction and the levels of dyspnea. Patients were stratified into three categories of no, one, and two or more moderate-to-severe exacerbations based on an analysis published in the literature. 24 Our results show that the majority of the health care costs in COPD patients are attributable to GP interactions. In patients with two or more (frequent) exacerbations, these accounted for 47% of total COPD costs whilst contributing 70% and 55% in patients with no and one exacerbation, respectively. A study by McGuire et al assessed the excess cost of chronic bronchitis and acute exacerbations of chronic bronchitis in the UK primary care setting. 8 They estimated that the excess cost of GP visits attributable to chronic bronchitis and acute exacerbations of chronic bronchitis was £6.5 million in England and Wales in 1997-1998. Our estimate of £23.3 million due to in-person GP visits and £61.8 million due to GP interactions in the CPRD sample alone is significantly higher.
A study reported by Wouters estimated the annual direct cost of COPD patients to be $1,254 in the UK in 2002, with mean annual GP visits per person being 6.6. 25 The estimated cost in our study was £1,826 in the pre-observation period 
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COPD costs in UK primary care and £2,108 during the observation period. We estimated the mean annual GP practice visits to be 12.7 among the entire cohort. This suggests a substantial increase in health care use in the primary care setting over the last 10 years. The Wouters study also reported 14% for patients with hospitalizations and 12% for emergency room visits. 25 We found 9.6% and 21.8% of patients reporting at least one hospitalization for COPD and non-COPD causes, respectively.
A study by Schermer et al estimated the costs associated with exacerbations in a primary care setting in the Netherlands. Their study reported annual costs of exacerbations as £40, £53, £61, and £92 among patients with no, mild, moderate, and severe airflow obstruction, respectively, in 2001. 26 The corresponding estimates in our study were £202, £233, £320, and £446, respectively. However, it is important to note that the severity classification used in the study by Schemer et al was based on the European Respiratory Society recommendation, 27 while ours was based on GOLD. 23 A study by Andersson et al showed that exacerbations account for 35%-45% of the total per capita health care costs for COPD. 28 In our study, which was mainly based on the primary care COPD population, exacerbations accounted for less than 25% of the costs, even for frequent exacerbators, highlighting a relatively small contribution of exacerbation costs to the overall COPD management costs. One possible explanation for the higher proportion of GP costs is the holistic assessment of GP interactions in our study. We included all forms of GP interactions, including non-GP-led interactions within and outside the surgery. Most other studies published in the literature have focused on surgery-based GP-led visits.
In our study, total COPD management costs and its cost components increased with increasing level of disease severity. This was more evident with increasing levels of dyspnea than with increasing levels of airflow obstruction, regardless of the exacerbation frequency. In part, this could be explained by more severe COPD patients having higher comorbidities and thus requiring more GP interactions and non-COPD hospitalization. This hypothesis, however, was not tested in the current study. A similar study by Tabberer et al estimated the incremental annual cost of moderateto-severe dyspnea in general practice to be in excess of £250 per patient. 29 Our estimates of the corresponding mean increase in annual COPD management costs with each level increase in dyspnea were £242, £357, and £466 for patients with no, one, and two or more exacerbations, respectively. Overall, the resource use costs increased with higher levels of exacerbation frequency and dyspnea.
Therefore, efforts to better manage patients in primary care with an aim to reduce exacerbations and symptoms that drive GP visits will help reduce overall COPD management costs significantly.
Our study has several limitations. We excluded the cost of non-exacerbation-related medications from our cost calculations. A previous study has shown medication cost to be a major contributor to overall health care costs. 8 This may significantly underestimate the annual COPD costs per patient in our analysis. We also used tariff-based cost estimates applicable across England and Wales. Whilst this improves the generalizability of our findings, the actual costs in local settings may differ from national estimates, thereby limiting their applicability to local health economies. Further, patients were included only if their information was available for at least 24 months. Such a condition of a longer stay in a cohort may introduce survival bias, given that patients with a higher disease severity and a higher risk of health care events do not survive for the full follow-up. In addition, the quality of spirometry data is unknown. One study indicated the possibility of a variable quality of spirometry measurement in a primary care population largely not included in the CPRD database.
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Conclusion
Estimated COPD management costs increased with exacerbation frequency and level of dyspnea based on data from 12 months of follow-up in an observational cohort study of patients managed in primary care. Interactions with GP surgery accounted for a substantial proportion of costs regardless of the exacerbation frequency. Further, the costs of GP interactions, exacerbations, and non-COPD hospitalizations increased with increasing levels of dyspnea. Therefore, in a primary care setting, better disease management focused on holistic assessment and reduction of symptoms is required. This is particularly applicable to patients with a low risk of exacerbations, who continue to utilize a significant proportion of health care resources. Future strategies should follow published guidelines such as GOLD to include systematic measurement of symptoms and health status, allowing physicians to identify patients with unmet need and treat them accordingly to improve individual outcomes and the collective burden.
